These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30275021)

  • 1. DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem.
    Ros J; Muñoz-Couselo E
    BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30275021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration.
    Maximova N; Maestro A; Zanon D; Marcuzzi A
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
    J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vemurafenib-induced DRESS/DIHS resulting in spontaneous melanoma regression: an immunological reaction shedding new light on melanoma treatment?
    Olteanu C; Scope A; Steinberg-Silman Y; Ziv M; Shear NH; Dodiuk-Gad RP; Markel G
    Int J Dermatol; 2020 May; 59(5):e139-e141. PubMed ID: 32212333
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
    Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
    J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
    [No Abstract]   [Full Text] [Related]  

  • 6. Early-Onset Vemurafenib-Induced DRESS Syndrome.
    Munch M; Peuvrel L; Brocard A; Saint Jean M; Khammari A; Dreno B; Quereux G
    Dermatology; 2016; 232(1):126-8. PubMed ID: 26418832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
    Grän F; Goebeler M; Gesierich A
    Eur J Dermatol; 2019 Feb; 29(1):107-108. PubMed ID: 30998207
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
    Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
    Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe skin eruption with features of drug reaction with eosinophilia and systemic symptoms (DRESS) during vemurafenib treatment of melanoma.
    Kohlmann J; Reschke R; Mockenhaupt M; Ziemer M
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):e242-e244. PubMed ID: 34704628
    [No Abstract]   [Full Text] [Related]  

  • 11. New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
    Diamantopoulos PT; Lakiotaki E; Kyriakakis G; Gogas H
    Melanoma Res; 2020 Apr; 30(2):206-208. PubMed ID: 31157737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
    Hopkins AM; Rathod AD; Rowland A; Kichenadasse G; Sorich MJ
    BMC Cancer; 2020 Feb; 20(1):157. PubMed ID: 32103736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cobimetinib.
    Signorelli J; Shah Gandhi A
    Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
    Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
    Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
    Keating GM
    Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
    Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
    Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vemurafenib-induced radiation recall dermatitis].
    Greliak A; Le Guern A; Bataille M; Lebas D; Wiart T; Modiano P
    Ann Dermatol Venereol; 2019 May; 146(5):382-384. PubMed ID: 30981540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
    Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.